Amphastar Q4 revenue misses estimates

Amphastar Pharmaceuticals,

26/02/2026 21:48

Overview

Biopharmaceutical firm's Q4 revenue miss analyst expectations

Adjusted EPS for Q4 missed analyst expectations

BAQSIMI sales increased due to higher unit volumes from U.S. marketing efforts

Outlook

Amphastar to scale U.S. manufacturing for growth phase

Result Drivers

BAQSIMI SALES - Increased due to higher unit volumes from U.S. marketing efforts

GLUCAGON SALES DECLINE - Decreased due to lower pricing and unit volumes amid competition

NEW PRODUCT LAUNCHES - Iron sucrose and other products contributed to revenue

Company press release: ID:nACSY4nRqa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$183.11 mln
$190.48 mln (6 Analysts)
Q4 Adjusted EPS
Miss
$0.73
$0.92 (7 Analysts)
Q4 EPS
$0.51
Q4 Adjusted Net Income
Miss
$34.16 mln
$43.60 mln (6 Analysts)
Q4 Net Income
$24.43 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Amphastar Pharmaceuticals Inc is $30.00, about 7.3% above its February 25 closing price of $27.97

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 7 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)